Oral Antidiyabetik Kullanımının, Farklılaşmış 3T3-L1 Hücrelerinde Adipogenez Metabolizmasında Görev Alan VDR, SIRT1, Apelin ve FOXO1 Gen Anlatım Seviyelerine Etkileri

Giriş: Yağ doku, obezite ve insülin direnci üzerindeki sistemik etkilere aracılık eden sitokinleri salgılamaktadır. Kullanılan antidiyabetik ilaçlar, 3T3-L1 adiposit hücrelerinde metabolik farklılıklar ve gen anlatım profillerinde farklılıklar oluşmaktadır. Çalışmamızda 3T3-L1 adipositlerde Vitamin D reseptörü (VDR), Sirtuin (SIRT1), Apelin ve Forkhead box protein O1 (FOXO1) gen anlatım seviyelerinin farklı oral antidiyabetik kullanımlarına cevaben değişimleri değerlendirildi. Yöntemler: 3T3-L1 hücreleri ATCC den temin edildi. Sitotoksisite testleri iCELLigence sistemi ile gerçek zamanlı olarak yapıldı. Çalışılan genler, gerçek zamanlı polimeraz zincir reaksiyonu (qPCR) ile belirlendi. Bulgular: Farklı oral antidiyabetik (akarboz, metformin ve glipizid) etken maddeleri uygulanan adiposit hücreleri kontrol adiposit hücreleri ile karşılaştırıldığında, VDR gen anlatım seviyeleri daha yüksek bulundu. SIRT1 ekspresyonu 6 saat 17 mg/ml akarboz, 6 saat 192 mM metformin ve 24 saat 180 μM glipizid uygulamasında kontrol adiposit hücrelerine kıyasla daha yüksek bulunurken, 6 saat 10 mg/ml akarboz ve 24 saat 175 mM metformin uygulamasında kontrol hücrelere göre daha düşük bulunmuştur (p=0.005). Apelin gen anlatım seviyelerini farklı oral antidiyabetik kullanımı ile kontrol hücrelere kıyasla azaldığı bulunmuştur (p=0.005). FOXO1 gen anlatım seviyesi 24 saat metfomin uygulaması dışında Adiposit hücrelerinde kontrole göre yüksek bulunmuştur (p=0.005). Sonuç: Sonuçlarımız, glipizid, akarboz ve metforminin obezitede yağ metabolizmasının düzenlenmesi üzerindeki faydalı etkilerine dair yeni fikirler vermesinin yanı sıra, terapötik yolakları hedefleyen çalışmalar için yeni stratejiler sağlayabilir düşüncesindeyiz.

Anahtar Kelimeler:

obezite, 3T3-L1 hücreleri, oral antidiyabetik, gen anlatımı

The Measurement of Neutrophil Gelatinase Associated Lipocalin in Umbilical Cord Blood and the Assessment of Its Relationship with Neonatal Results

Objectives: In this study, the relationship of cord blood Neutrophil Gelatinase-Associated Lipocalin (NGAL) with neonatal diseases was investigated. Methods: NGAL levels were measured in the cord blood of 180 babies born between 2015 and 2016. Patients were classified according to maternal diseases, neonatal diseases and demographic characteristics. Obtained data were compared with cord blood NGAL levels. Results: In our study, the mean NGAL levels were 1283.99 ng/mL in boys and 1306.52 ng/mL in girls. Umbilical cord blood NGAL levels of infants diagnosed with intrauterine growth retardation (1913.4±2833.5 ng/mL) and prolonged premature rupture of membranes (2594.2±2037.1 ng/mL) were found to be statistically high (p0.05). Conclusions: Neutrophil Gelatinase-Associated Lipocalin, may be useful as a diagnostic biomarker in the evaluation of maternal and neonatal diseases. However, studies on larger patient populations are needed.

Keywords:

Neutrophil Gelatinase Associated Lipocalin, umbilical cord blood, newborn,

PDF

___

1. Wang N, Wang N, Luo G, et al. Lutein attenuates excessive lipid accumulation in differentiated 3T3- L1 cells and abdominal adipose tissue of rats by the SIRT1-mediated pathway. Int J Biochem Cell Biol. 2021; 133: 1357-2725.
2. Güven M. Association of Initial HbA1c Level with Obesity Medical Treatment Success in Morbidly Obese Patients. Dicle Med J. 2021; 48: 316-27.
3. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav. 2008; 94: 206–18.
4. Crowley VE. Overview of human obesity and central mechanisms regulating energy homeostasis. Ann Clin Biochem. 2008; 45: 245–55.
5. Wong KE, Kong J, Zhang W, et al. Targeted Expression of Human Vitamin D Receptor in Adipocytes Decreases Energy Expenditure and Induces Obesity in Mice. J Biol Chem. 2011; 30: 33804-10.
6. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev. 2008; 29: 726–76.
7. Kong J, Li YC. Molecular mechanism of 1,25- dihydroxyvitamin D3 inhibition of adipogenesis in 3T3-L1 cells. Am J Physiol Endocrinol Metab. 2006; 290: 916–24.
8. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature. 2009; 460: 587–91.
9. Kwon HS, Ott M. The ups and downs of SIRT1. Trends Biochem Sci. 2008; 33: 517–25.
10. Sinclair DA, Guarente L. Unlocking the secrets of longevity genes. Sci Am. 2006; 294: 48–51, 54–7.
11. Hayashida S, Arimoto A, Kuramoto Y, et al. Fasting promotes the expression of SIRT1, an NADþ -dependent protein deacetylase, via activation of PPARalpha in mice. Mol Cell Biochem. 2010; 339: 285–92.
12. Picard F, Kurtev M, Chung N, et al. SIRT1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature. 2004; 429: 771–6.
13. Mayoral R, Osborn O, McNelis J, et al. Adipocyte SIRT1 knockout promotes PPARgamma activity, adipogenesis and insulin sensitivity in chronic-HFD and obesity. Mol Metab. 2015; 4: 378–91.
14. Yuzbashian E, Zarkesh M, Asghari G, et al. Is apelin gene expression and concentration affected by dietary intakes? A systematic review. Crit Rev Food Sci Nutr. 2018; 58: 680-8.
15. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146:1764–71.
16. Ringstrom C, Nitert MD, Bennet H, et al. Apelin is a novel islet peptide. Regul Pept. 2010; 162: 44–51.
17. Dray C, Knauf C, Daviaud D, et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab. 2008; 8: 437–45.
18. Wei L, Hou X, Tatemoto K. Regulation of apelin mRNA expression by insulin and glucocorticoids in mouse 3T3-L1 adipocytes. Regul Pept. 2005; 132: 27–32.
19. Monsalve M, Olmos Y. The complex biology of FOXO. Curr Drug Targets. 2011; 12: 1322–50.
20. Kousteni S. FoxO1, the transcriptional chief of staff of energy metabolism. Bone. 2012; 50: 437–43.
21. Miard S, Dombrowski L, Carter S, et al. Aging alters PPARgamma in rodent and human adipose tissue by modulating the balance in steroid receptor coactivator-1. Aging Cell. 2009; 8: 449-59.
22. Lillie RD and Ashburn LL. Supersaturated solutions of fat stains in dilute isopropanol for demonstration of acute fatty degeneration not shown by Herxheimer’s technique. Archs Path. 1943; 36; 432-40.
23. Hammes TO, dos Santos Costa C, Rohden F, et al. Parallel down-regulation of FOXO1, PPARγ and adiponectin mRNA expression in visceral adipose tissue of class III obese individuals. Obes Facts. 2012; 5: 452-9.
24. Caton PW, Kieswich J, Yaqoob MM, et al. Metformin opposes impaired AMPK and SIRT1 function and deleterious changes in core clock protein expression in white adipose tissue of genetically-obese db/db mice. Diabetes Obesity and Metabolism. 2011; 13: 1097–104.
25. Castan-Laurell I, Dray C, Valet P. The therapeutic potentials of apelin in obesity-associated diseases. Molecular and Cellular Endocrinology. 2021; 529: 111278.
26. Stelmaszyk A, Mikołajczak P, Dworacka M. Sirtuin 1 as the mechanism of action of agents used in the diabetes mellitus pharmacotherapy. European Journal of Pharmacology. 2021; 907: 174289.
27. Lettieri Barbato D, Tatulli G, Aquilano K, et al. FoxO1 controls lysosomal acid lipase in adipocytes: implication of lipophagy during nutrient restriction and metformin treatment. Cell Death Dis. 2013; 17; 4: e861-e861.